Discussion
PG has an annual incidence of 3-10 per million persons, most commonly presents between 20 and 50 years of age and is more common in women. It is characterized by a neutrophilic infiltrate that is believed to be due to dysregulation of neutrophil function and altered innate immune responses. It frequently presents as painful ulcers that often follow surgery or trauma and is commonly misdiagnosed as infectious or ischemic lesions [1] .
Initial therapy consists of corticosteroids, although steroid-sparing agents have been used, including dapsone, minocycline, methotrexate, cyclosporine, mycophenolate and TNFα inhibitors. IVIG is typically used after other treatments have failed. Careful wound care and avoidance of debridement and surgery is key [1] .
We reviewed 20 cases of IVIG therapy in PG that are described in table 1 and table 2 . Table 1 describes 13 cases that were treated with IVIG 2 g/kg (except for two in whom the dose was 1.5 and 2.5 g/kg, respectively). 12 of these achieved complete or nearly complete remission; 2 had disease recurrence that required repeated courses of IVIG. Both instances of recurrent disease responded to repeat treatment with IVIG. Table 2 describes 7 patients treated with lower-dose IVIG (0.5 g/kg). All had major or complete response, though all required continued corticosteroids, with 4 requiring additional immunosuppressive therapy.
Based on this case and our review of the literature, we believe that IVIG is a useful therapeutic option in refractory PG and can be considered in cases of resistance to or intolerance of standard immunomodulatory therapy.
This work was conducted at the University of Alabama, Birmingham, USA.
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